Product Code: TMRGL84870
The report provides revenue of the global venous diseases treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global venous diseases treatment market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the venous diseases treatment market.
The report delves into the competitive landscape of the global venous diseases treatment market. Key players operating in the global venous diseases treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global venous diseases treatment market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Venous Diseases Treatment Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Segment Definition
- 4.1.2. Industry Evolution / Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Porter's Five Force Analysis
5. Key Insights
- 5.1. Regulatory Scenario by Region/globally
- 5.2. Technological Advancements
- 5.3. Pipeline Analysis
- 5.4. Key Mergers & Acquisitions
- 5.5. Disease Prevalence & Incidence Rate globally with key countries
- 5.6. Reimbursement Scenario by Region/globally
6. Global Venous Diseases Treatment Analysis and Forecast, by Treatment Type
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Treatment, 2017-2031
- 6.3.1. Surgeries
- 6.3.1.1. Angioplasty or Stenting
- 6.3.1.2. Vein Ligation and Stripping
- 6.3.1.3. Vena Cava Filter
- 6.3.1.4. Ambulatory Phlebectomy
- 6.3.1.5. Others
- 6.3.2. Therapies
- 6.3.2.1. Sclerotherapy
- 6.3.2.2. Radiofrequency Ablation Therapy
- 6.3.2.3. Laser Treatment
- 6.4. Market Attractiveness Analysis, by Treatment
7. Global Venous Diseases Treatment Analysis and Forecast, by Disease Type
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Disease Type, 2017-2031
- 7.3.1. Deep-vein Thrombophlebitis
- 7.3.2. Varicose Veins
- 7.3.3. Superficial Thrombophlebitis
- 7.3.4. Chronic Venous Insufficiency
- 7.3.5. Venous Ulcers
- 7.3.6. Others
- 7.4. Market Attractiveness Analysis, by Disease Type
8. Global Venous Diseases Treatment Analysis and Forecast, by Product Type
- 8.1. Introduction & Definition
- 8.2. Key Findings / Developments
- 8.3. Market Value Forecast, by Product Type, 2017-2031
- 8.3.1. Ablation Devices
- 8.3.2. Venous Stents
- 8.3.3. Venous Closure Treatments
- 8.3.4. Sclerotherapy Injection
- 8.3.5. Others
- 8.4. Market Attractiveness Analysis, by Product Type
9. Global Venous Diseases Treatment Analysis and Forecast, by End-user
- 9.1. Introduction & Definition
- 9.2. Key Findings / Developments
- 9.3. Market Value Forecast, by End-user, 2017-2031
- 9.3.1. Hospitals
- 9.3.2. Clinics
- 9.3.3. Ambulatory centers
- 9.4. Market Attractiveness Analysis, by End-user
10. Global Venous Diseases Treatment Analysis and Forecast, by Region
- 10.1. Key Findings
- 10.2. Market Value Forecast, by Region
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
- 10.3. Market Attractiveness Analysis, by Region
11. North America Venous Diseases Treatment Analysis and Forecast
- 11.1. Introduction
- 11.2. Market Value Forecast, by Treatment, 2017-2031
- 11.2.1. Surgeries
- 11.2.1.1. Angioplasty or Stenting
- 11.2.1.2. Vein Ligation and Stripping
- 11.2.1.3. Vena Cava Filter
- 11.2.1.4. Ambulatory Phlebectomy
- 11.2.1.5. Others
- 11.2.2. Therapies
- 11.2.2.1. Sclerotherapy
- 11.2.2.2. Radiofrequency Ablation Therapy
- 11.2.2.3. Laser Treatment
- 11.3. Market Value Forecast, by Disease Type, 2017-2031
- 11.3.1. Deep-vein Thrombophlebitis
- 11.3.2. Varicose Veins
- 11.3.3. Superficial Thrombophlebitis
- 11.3.4. Chronic Venous Insufficiency
- 11.3.5. Venous Ulcers
- 11.3.6. Others
- 11.4. Market Value Forecast, by Product Type, 2017-2031
- 11.4.1. Ablation Devices
- 11.4.2. Venous Stents
- 11.4.3. Venous Closure Treatments
- 11.4.4. Sclerotherapy Injection
- 11.4.5. Others
- 11.5. Market Value Forecast, by End-user, 2017-2031
- 11.5.1. Hospitals
- 11.5.2. Clinics
- 11.5.3. Ambulatory centers
- 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.6.1. U.S.
- 11.6.2. Canada
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Treatment
- 11.7.2. By Disease Type
- 11.7.3. By Product Type
- 11.7.4. By End-user
- 11.7.5. By Country/Sub-region
12. Europe Venous Diseases Treatment Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Treatment, 2017-2031
- 12.2.1. Surgeries
- 12.2.1.1. Angioplasty or Stenting
- 12.2.1.2. Vein Ligation and Stripping
- 12.2.1.3. VeEnd Use Cava Filter
- 12.2.1.4. Ambulatory Phlebectomy
- 12.2.1.5. Others
- 12.2.2. Therapies
- 12.2.2.1. Sclerotherapy
- 12.2.2.2. Radiofrequency Ablation Therapy
- 12.2.2.3. Laser Treatment
- 12.3. Market Value Forecast, by Disease Type, 2017-2031
- 12.3.1. Deep-vein Thrombophlebitis
- 12.3.2. Varicose Veins
- 12.3.3. Superficial Thrombophlebitis
- 12.3.4. Chronic Venous Insufficiency
- 12.3.5. Venous Ulcers
- 12.3.6. Others
- 12.4. Market Value Forecast, by Product Type, 2017-2031
- 12.4.1. Ablation Devices
- 12.4.2. Venous Stents
- 12.4.3. Venous Closure Treatments
- 12.4.4. Sclerotherapy Injection
- 12.4.5. Others
- 12.5. Market Value Forecast, by End-user, 2017-2031
- 12.5.1. Hospitals
- 12.5.2. Clinics
- 12.5.3. Ambulatory centers
- 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.7. Market Attractiveness Analysis
- 12.7.1. By Treatment
- 12.7.2. By Disease Type
- 12.7.3. By Product Type
- 12.7.4. By End-user
- 12.7.5. By Country/Sub-region
13. Asia Pacific Venous Diseases Treatment Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Treatment, 2017-2031
- 13.2.1. Surgeries
- 13.2.1.1. Angioplasty or Stenting
- 13.2.1.2. Vein Ligation and Stripping
- 13.2.1.3. VeEnd Use Cava Filter
- 13.2.1.4. Ambulatory Phlebectomy
- 13.2.1.5. Others
- 13.2.2. Therapies
- 13.2.2.1. Sclerotherapy
- 13.2.2.2. Radiofrequency Ablation Therapy
- 13.2.2.3. Laser Treatment
- 13.3. Market Value Forecast, by Disease Type, 2017-2031
- 13.3.1. Deep-vein Thrombophlebitis
- 13.3.2. Varicose Veins
- 13.3.3. Superficial Thrombophlebitis
- 13.3.4. Chronic Venous Insufficiency
- 13.3.5. Venous Ulcers
- 13.3.6. Others
- 13.4. Market Value Forecast, by Product Type, 2017-2031
- 13.4.1. Ablation Devices
- 13.4.2. Venous Stents
- 13.4.3. Venous Closure Treatments
- 13.4.4. Sclerotherapy Injection
- 13.4.5. Others
- 13.5. Market Value Forecast, by End-user, 2017-2031
- 13.5.1. Hospitals
- 13.5.2. Clinics
- 13.5.3. Ambulatory centers
- 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Treatment
- 13.7.2. By Disease Type
- 13.7.3. By Product Type
- 13.7.4. By End-user
- 13.7.5. By Country/Sub-region
14. Latin America Venous Diseases Treatment Analysis and Forecast
- 14.1. Introduction
- 14.2. Market Value Forecast, by Treatment, 2017-2031
- 14.2.1. Surgeries
- 14.2.1.1. Angioplasty or Stenting
- 14.2.1.2. Vein Ligation and Stripping
- 14.2.1.3. VeEnd Use Cava Filter
- 14.2.1.4. Ambulatory Phlebectomy
- 14.2.1.5. Others
- 14.2.2. Therapies
- 14.2.2.1. Sclerotherapy
- 14.2.2.2. Radiofrequency Ablation Therapy
- 14.2.2.3. Laser Treatment
- 14.3. Market Value Forecast, by Disease Type, 2017-2031
- 14.3.1. Deep-vein Thrombophlebitis
- 14.3.2. Varicose Veins
- 14.3.3. Superficial Thrombophlebitis
- 14.3.4. Chronic Venous Insufficiency
- 14.3.5. Venous Ulcers
- 14.3.6. Others
- 14.4. Market Value Forecast, by Product Type, 2017-2031
- 14.4.1. Ablation Devices
- 14.4.2. Venous Stents
- 14.4.3. Venous Closure Treatments
- 14.4.4. Sclerotherapy Injection
- 14.4.5. Others
- 14.5. Market Value Forecast, by End-user, 2017-2031
- 14.5.1. Hospitals
- 14.5.2. Clinics
- 14.5.3. Ambulatory centers
- 14.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
- 14.6.1. Brazil
- 14.6.2. Mexico
- 14.6.3. Rest of Latin America
- 14.7. Market Attractiveness Analysis
- 14.7.1. By Treatment
- 14.7.2. By Disease Type
- 14.7.3. By Product Type
- 14.7.4. By End-user
- 14.7.5. By Country/Sub-region
15. Middle East & Africa Venous Diseases Treatment Analysis and Forecast
- 15.1. Introduction
- 15.2. Market Value Forecast, by Treatment, 2017-2031
- 15.2.1. Surgeries
- 15.2.1.1. Angioplasty or Stenting
- 15.2.1.2. Vein Ligation and Stripping
- 15.2.1.3. VeEnd Use Cava Filter
- 15.2.1.4. Ambulatory Phlebectomy
- 15.2.1.5. Others
- 15.2.2. Therapies
- 15.2.2.1. Sclerotherapy
- 15.2.2.2. Radiofrequency Ablation Therapy
- 15.2.2.3. Laser Treatment
- 15.3. Market Value Forecast, by Disease Type, 2017-2031
- 15.3.1. Deep-vein Thrombophlebitis
- 15.3.2. Varicose Veins
- 15.3.3. Superficial Thrombophlebitis
- 15.3.4. Chronic Venous Insufficiency
- 15.3.5. Venous Ulcers
- 15.3.6. Others
- 15.4. Market Value Forecast, by Product Type, 2017-2031
- 15.4.1. Ablation Devices
- 15.4.2. Venous Stents
- 15.4.3. Venous Closure Treatments
- 15.4.4. Sclerotherapy Injection
- 15.4.5. Others
- 15.5. Market Value Forecast, by End-user, 2017-2031
- 15.5.1. Hospitals
- 15.5.2. Clinics
- 15.5.3. Ambulatory centers
- 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
16. Competitive Landscape
- 16.1. Market Player - Competition Matrix (by tier and size of companies)
- 16.2. Market Share Analysis, by Company, 2021
- 16.3. Company Profiles
- 16.3.1. Zimmer Biomet Holdings, Inc.
- 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.1.2. Company Financials
- 16.3.1.3. Growth Strategies
- 16.3.1.4. SWOT Analysis
- 16.3.2. Medtronic
- 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.2.2. Company Financials
- 16.3.2.3. Growth Strategies
- 16.3.2.4. SWOT Analysis
- 16.3.3. AngioDynamics
- 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.3.2. Company Financials
- 16.3.3.3. Growth Strategies
- 16.3.3.4. SWOT Analysis
- 16.3.4. Alma Lasers
- 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.4.2. Company Financials
- 16.3.4.3. Growth Strategies
- 16.3.4.4. SWOT Analysis
- 16.3.5. Biolitec AG Untere Viaduktgasse
- 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.5.2. Company Financials
- 16.3.5.3. Growth Strategies
- 16.3.5.4. SWOT Analysis
- 16.3.6. Becton, Dickinson and Company
- 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.6.2. Company Financials
- 16.3.6.3. Growth Strategies
- 16.3.6.4. SWOT Analysis
- 16.3.7. Boston Scientific Corporation
- 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.7.2. Company Financials
- 16.3.7.3. Growth Strategies
- 16.3.7.4. SWOT Analysis
- 16.3.8. Abbott Laboratories
- 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.8.2. Company Financials
- 16.3.8.3. Growth Strategies
- 16.3.8.4. SWOT Analysis
- 16.3.9. B. Braun Melsungen AG
- 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.9.2. Company Financials
- 16.3.9.3. Growth Strategies
- 16.3.9.4. SWOT Analysis
- 16.3.10. Teleflex Incorporated
- 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.10.2. Company Financials
- 16.3.10.3. Growth Strategies
- 16.3.10.4. SWOT Analysis
- 16.3.11. Lumenis
- 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.11.2. Company Financials
- 16.3.11.3. Growth Strategies
- 16.3.11.4. SWOT Analysis
- 16.3.12. Philips
- 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.12.2. Company Financials
- 16.3.12.3. Growth Strategies
- 16.3.12.4. SWOT Analysis